Patents by Inventor Joaquin Castilla Castrillon

Joaquin Castilla Castrillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of ciclopirox as a modulator of the heme group biosynthesis and in the treatment of porphyrias and other diseases
    Patent number: 11337966
    Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 24, 2022
    Assignee: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE
    Inventors: Oscar Millet Aguilar-Galindo, Arantza Sanz Parra, Ana Laín Torre, Pedro David Urquiza Ortiz, Juan Manuel Falcón Pérez, Joaquín Castilla Castrillón, Itxaso San Juan Quintana, Ganeko Bernardo-Seisdedos
  • USE OF CICLOPIROX AS A MODULATOR OF THE HEME GROUP BIOSYNTHESIS AND IN THE TREATMENT OF PORPHYRIAS AND OTHER DISEASES
    Publication number: 20200171013
    Abstract: The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 4, 2020
    Inventors: Oscar MILLET AGUILAR-GALINDO, Arantza SANZ PARRA, Ana LAÍN TORRE, Pedro David URQUIZA ORTIZ, Juan Manuel FALCÓN PÉREZ, Joaquín CASTILLA CASTRILLÓN, Itxaso SAN JUAN QUINTANA, Ganeko BERNARDO-SEISDEDOS
  • Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
    Patent number: 7041300
    Abstract: The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located on ends 3? and 5?, further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication and encapsidation. These vectors are suitable for the forming of a recombinant system comprising the aforesaid expression vector, and a helper virus. The system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of different animal species, especially pigs, dogs and cats, and as expression vehicles for antibodies protective against infectious agents.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: May 9, 2006
    Assignee: Cyanamid Iberica, S.A.
    Inventors: Luis Enjuanes Sanchez, Juan Plana Duran, Sara Alonso Villanueva, MaLuisa Ballesteros Jarreno, Joaquin Castilla Castrillon, José Manuel Gonzalez Martinez, Ander Izeta Parmesan, Ana Mendez Zunzunegui, Maria Muntion Saenz, Zoltán Penzes, José Manuel Sanchez Morgado, Carlos Miguel Sanchez Sanchez, Cristina Smerdou Picazo, Isabel Sola Gurpegui
  • Vectors based on recombinant defective viral genomes and their use in the formulation of vaccines
    Publication number: 20040052775
    Abstract: The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located on ends 3′ and 5′, further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication and encapsidation. These vectors are suitable for the forming of a recombinant system comprising the aforesaid expression vector, and a helper virus. The system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of different animal species, especially pigs, dogs and cats, and as expression vehicles for antibodies protective against infectious agents.
    Type: Application
    Filed: May 23, 2003
    Publication date: March 18, 2004
    Inventors: Luis Enjuanes Sanchez, Juan Plana Duran, Sara Alonso Villanueva, M?apos;Luisa Ballesteros Jarreno, Joaquin Castilla Castrillon, Jose Manuel Gonzales Martinez, Ander Izeta Parmesan, Ana Mendez Zunzunegui, Maria Muntion Saenz, Zoltan Penzes, Jose Manuel Sanchez Morgado, Carlos Miguel Sanchez Sanchez, Cristina Smerdou Picazo, Isabel Sola Gurpegui